GlassScriptPhysician profile
Frederick J Nahas, II
NPI 1659397297
$5,288.19
in general payments reported to CMS, 2019-2025
32 companies · $562 in 2025
The $562 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $259 · 2021: $255 · 2022: $491 · 2023: $627 · 2024: $1,963 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,626 · Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,625.97 |
| Food and Beverage | $1,525.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,713.39 | 2024 | |
| Abbvie INC. | $758.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $335.74 | 2022-2024 | Breztri, Farxiga |
| Allergan, INC. | $331.67 | 2019-2020 | |
| Insmed, INC. | $237.08 | 2019-2022 | |
| Novo Nordisk INC | $206.90 | 2019-2025 | Ozempic |
| Cardiovascular Systems INC. | $204.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.41 | 2020-2023 | Jardiance |
| Gilead Sciences, INC. | $124.93 | 2019 | |
| Ferring Pharmaceuticals INC. | $123.58 | 2023 | Rebyota |
| Lilly USA, LLC | $122.53 | 2023 | Mounjaro |
| Amarin Pharma, INC. | $117.44 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $111.02 | 2019 | |
| Nestle Healthcare Nutrition INC. | $108.08 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $102.27 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $96.92 | 2025 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $74.58 | 2019 | |
| Integra Lifesciences Corporation | $56.55 | 2021-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Qol Medical, LLC | $44.23 | 2024-2025 | Sucraid, Sucraid |
| Arbor Pharmaceuticals, INC. | $33.32 | 2021-2022 | |
| Baxter Healthcare | $31.99 | 2020 | |
| Smith+Nephew, INC. | $31.98 | 2021-2025 | Collagenase Santyl |
| Davol INC. | $29.46 | 2020 | |
| Tactile Systems Technology INC | $27.41 | 2025 | Flexitouch Plus, Nimbl |
| Janssen Biotech, INC. | $17.74 | 2025 | Tremfya |
| Lemaitre Vascular, INC. | $16.20 | 2021 | |
| Amgen INC. | $14.26 | 2019 | |
| Corcept Therapeutics | $14.17 | 2022 | |
| Merck Sharp & Dohme LLC | $14.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.57 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.29 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Nahas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.